Clinical Trial: Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy

U.S., May 7 -- ClinicalTrials.gov registry received information related to the study (NCT06958705) titled 'Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy' on April 08.

Brief Summary: This is an open-label, multicenter, phase 2, non-randomized study aiming to study the efficacy and safety of fixed-duration venetoclax consolidation in CLL patients who are on BTK inhibitor monotherapy. Patients who are on BTK inhibitor monotherapy for >= 6 months and still responsive are included. The study includes patients who are treatment-naive before taking BTK inhibitors. Patients will be treated with the BTK inhibitor plus full-dose venetoclax for 12 cycles after a standard 5-week dose ramp-up. Peripheral blood and b...